clinical trial · NCT06717932
A Follow-up Study to Evaluate the Long-term Safety and Efficacy in Participants Who Received CS-101 Injection
CorrectSequence Therapeutics Co., Ltd·—·enrolling by invitation·n = 8
Beta-Thalassemia
brief summary
This is a study to evaluate the long-term safety and efficacy of CS-101 in participants who received CS-101 in study CS -101-01 (NCT06291961),No investigational drug product will be administered in the study.
started
May 15, 2025
primary completion
Nov 1, 2039
completion
Nov 1, 2039
last updated
Feb 10, 2026
detailed description
This is a study to evaluate the long-term safety and efficacy of CS-101 in participants who received CS-101 in study CS -101-01 (NCT06291961). Subjects in the CS-101-01 study will be entered into long-term follow-up of this study up to 15 years post-infusion at the completion of the last (12-month) follow up visit after treatment with CS-101 Injection.
official title
A Long-term Follow-up Study Evaluating the Safety and Efficacy of Subjects With β-thalassemia Treated With CS-101 Transplantation
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol